Philippe Monteyne, speaking at World Orphan Drug Congress 2011

Philippe Monteyne,
SVP, Head of Development & CMO
GSK

Philippe Monteyne, MD, PhD is Senior Vice President - Head of Development and Chief Medical Officer, GSK Rare Diseases. He reports to Marc Dunoyer, GSK's Chairman Japan, who is leading the new GSK special unit created in 2010. This unit is specialised in the development and commercialisation of medicines for rare diseases. In this new role, Philippe oversees early and late development activities, including worldwide clinical and regulatory strategies and leading to the launch of internal or newly acquired assets in the field of orphan drugs. Philippe and his team also work in close collaboration with all the discovery organisations of GSK including Biopharma, Oncology, R&D China, as well as all other R&D Discovery Units of GSK to ensure the appropriate transition when internal assets move from Discovery to this newly formed Rare Diseases Unit.
Philippe is also a visiting Professor of Neurosciences at UCL, Catholic University of Louvain in Belgium.

Appearing:

World Orphan Drug Congress Day 2 Wednesday 30th November 2011

4.45pm

Panel discussion: From big pharma to niche specialist: lessons learned from rare disease collaborations

What have been the strategies of big pharma and how are they engaging in partnerships?
How are drug candidates selected for backing outside of the internal research walls?
What are the future responsibilities of patient groups within research alliances?
How do biotechs and specialised pharma companies assess potential partnering?

Dr. Alvin Shih,

Director, Orphan and Genetic Diseases,
Pfizer

Philippe Monteyne,

SVP, Head of Development & CMO,
GSK

Jörn Aldag,

CEO,
Amsterdam Molecular Therapeutics

Frédéric Revah,

CEO,
Genethon

Sponsor World Orphan Drug Congress 2011 ›

Associate Sponsor